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Abstract 26 
Copper(II) complexes synthesized from the products of condensation of S-methyl- and S-27 
benzyldithiocarbazate (SMHDH2 and SBHDH2 respectively) with 2,5-hexandione have been 28 
characterized using various physico-chemical (elemental analysis, molar conductivity, 29 
magnetic susceptibility) and spectroscopic (infrared, electronic) methods. The structures of 30 
SMHDH2, its copper(II) complex CuSMHD, the related CuSBHD as well as the pyrrole 31 
byproduct SBPY have been determined by single crystal X-ray diffraction. In order to 32 
provide more insight into the behaviour of the complexes in solution, electron paramagnetic 33 
resonance (EPR) and electrochemical experiments were performed. The antibacterial and 34 
anticancer activities of both ligands and complexes were evaluated. The compounds, 35 
dissolved in 0.5% and 5% DMSO, showed a wide range of antimicrobial activity against 10 36 
strains of Gram-positive and Gram-negative bacteria. Investigation of the effects of efflux 37 
pumps and membrane penetration towards the antibacterial activity are reported herein. The 38 
antiproliferation activity of the compounds was observed to be enhanced upon complexation. 39 
Both Cu complexes are strongly active against human breast adenocarcinoma cancer cell 40 
lines MDA-MB-231 and MCF-7.   41 
  42 
2 
 
TOC diagram 43 
 44 
  45 
3 
 
1. Introduction 46 
 47 
Effective treatment of multi-drug resistant (MDR) bacterial infections has become 48 
increasingly challenging as the efficiency of the available antibiotic arsenal is reduced, 49 
resulting in increased frequency of therapeutic failure [1, 2]. One resistance pathway of MDR 50 
bacteria involves over-expression of efflux pumps, which expel structurally unrelated 51 
antibiotics causing a decrease in their intracellular concentration [3, 4]. It is essential to 52 
understand efflux-mediated resistance in bacterial pathogens to develop new antibacterial 53 
agents. In addition, parallel concerns relating to acquired drug resistance of current anticancer 54 
drugs as well as their serious side-effects in the midst of the increasing rate of cancer 55 
diagnoses, in particular breast cancer, drives the effort to develop better alternatives [5, 6]. 56 
Dithiocarbazate compounds with their plethora of potentially tunable biological activities are 57 
exciting candidates for exploration and development.  58 
 59 
The sulphur-nitrogen chelating agents derived from S-alkyl/aryl esters of dithiocarbazic 60 
acid have been extensively investigated in recent years for their potential anticancer [7, 8], 61 
antibacterial [9], antiamoebic [10], anti-Trypanosoma cruzi [11] and anti-Mycobacterium 62 
tuberculosis [12] activities. Considerable attention continues to be given to these and related 63 
Schiff base ligands [13-16], since their properties can be modulated by introducing different 64 
substituents through condensation of various S-substituted dithiocarbazate esters with a wide 65 
array of aldehydes and ketones. In many cases, the biological properties of dithiocarbazate 66 
derivatives have been shown to be widely different although there may be only slight 67 
variation in their molecular structures [8]. Since these ligands possess both hard nitrogen and 68 
soft sulfur donor atoms they are capable of coordinating with a wide range of transition and 69 
non-transition metal ions forming metal complexes with interesting physicochemical and 70 
enhanced biological properties [17-19]. The wide diversity of structures displayed by 71 
macrocyclic and macroacyclic Schiff bases [20] result in various coordination abilities and 72 
lead to potential applications in biology ranging from therapeutics to diagnostics [21]. In 73 
addition, these compounds provide synthetic models for metalloproteins and metalloenzymes 74 
[22]. As part of our ongoing exploration of these interesting properties, we investigated the 75 
synthesis and characterization of some macroacyclic bis(dithiocarbazato) Schiff bases and 76 
their Cu(II) complexes in this work. The title compounds are analogues of the copper(II) 77 
bis(thiosemicarbazones) that have garnered much attention particularly as 78 
radiopharmaceuticals for the specific targeting of hypoxic tissue [23]. It was anticipated that 79 
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replacing nitrogen in thiosemicarbazones with sulphur might provide interesting results.  2,5-80 
hexanedione was chosen to form the Schiff bases to enhance ligand flexibility, thereby 81 
facilitating increased tetrahedral distortion which could lead to incorporation of metal cations, 82 
such as Cu(I), that generally prefer non-square planar geometries [24]. It has been 83 
definitively shown that biological activity is related to the geometry at the metal site and, in 84 
the investigation of SOD mimics, it was noted that complexes with more pronounced 85 
tetrahedral distortion display higher activity [25, 26]. Copper complexes derived from 86 
thiosemicarbazate have been subjected to intensive research and appeared to be very efficient 87 
as antimicrobial [27] and anticancer [28] agents. The copper(II) complexes of NNSS ligands 88 
reported in the literature are also known to be neutral, stable (Kass=1018) compounds that 89 
easily cross cellular membranes [23, 29]. Thus, it is logical that copper ion serve as an 90 
excellent choice in our continuous search for effective metallodrugs.  91 
 92 
The main aim of the present work is to explore the biological potential of Cu(II) 93 
bis(dithiocarbazate) complexes by determining their cytotoxicity and their potencies against 94 
different bacterial strains expressing a multi-drug resistance phenotype. Whereas syntheses of 95 
many dithiocarbazate compounds have been reported in the literature, there are only limited 96 
reports on the bioactivities [30], crystallography, EPR and electrochemistry [31, 32] with 97 
Cu(II) bis(dithiocarbazate). To promote effective bioactivities, it is essential to orient effort 98 
towards correlating the biological activities of this class of compounds with their solid and 99 
solution structures as well as their physico-chemical properties to identify the optimum 100 
geometry about the Cu ion. This goal can be achieved through the synthesis of a graduated 101 
series of ligands designed to reveal the mode of bioaction. 102 
 103 
2. Results and Discussion 104 
2.1. Synthesis and characterization  105 
The synthesis of S-substituted dithiocarbazates was performed as previously 106 
described [33, 34]. Carbon disulfide and hydrazine were reacted in basic ethanol. After 107 
workup, the dithiocarbazate produced was directly reacted with methyl iodide or benzyl 108 
chloride to afford S-methyldithiocarbazate (SMDTC) and S-benzyldithiocarbazate (SBDTC), 109 
respectively. Schiff bases were then prepared by a slight variation of the method described by 110 
Ali et al. [35]. The respective S-substituted dithiocarbazates and 2,5-hexandione were 111 
condensed in 2:1 ratio (Scheme 1). The initial attempts to synthesize the ligand SBHDH2 112 
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(Scheme 2) with prolonged heating followed by purification using column chromatography 113 
were unsuccessful. NMR, ESI, elemental analysis and single crystal X-ray diffraction 114 
confirmed cyclization to the pyrrole derivative. We postulate that bis(dithiocarbazate) indeed 115 
formed but subsequently hydrolyzed to mono(dithiocarbazate) and S-benzyldithiocarbazate 116 
[36, 37] with subsequent cyclization of the mono(dithiocarbazate) to a pyrrole via the Paal-117 
Knorr reaction. To our knowledge, this is the first pyrrole reported to be derived from a 118 
dithiocarbazate although there are two recent reports of formation of pyrrole byproducts  119 
upon reaction of thiosemicarbazone with 2,5-hexandione [38, 39]. Encouraged by the 120 
remarkable pharmacological properties of functionalized pyrrole [40, 41], we tested the 121 
compound for its antimicrobial activity, the results of which are discussed below. The Schiff 122 
base, SBHDH2, was finally obtained using either of the following two methods:  stirring the 123 
dione and SBDTC at room temperature for 30 minutes or heating for only 5 minutes after 124 
which the white precipitate formed immediately. SMHDH2 was synthesized without the 125 
complication of side-reaction occurrence. The precipitate was recrystallized to afford pure 126 
SMHDH2 (70% yield). 127 
 128 
Cu(II) complexes with NNSS coordination were obtained from the reaction of 129 
copper(II) acetate with equimolar amounts of the respective ligand (in acetonitrile for 130 
SBHDH2 and methanol for SMHDH2). The complexes were isolated by filtration with yields 131 
of 77% and 73% for CuSMHD and CuSBHD, respectively. Black crystals were grown from 132 
acetonitrile.   133 
 134 
Scheme 1. Synthesis of the copper complexes derived from bis(dithiocarbazate) ligands. a) 135 
CS2, KOH, EtOH, 0°C, 1 hour; b) CH3I or PhCH2Cl, EtOH, 0°C, 5 hr; c) for SMHDH2 (2,5-136 
hexanedione, EtOH, 79°C, 1 hour), for SBHDH2 (2,5-hexanedione, EtOH, 79°C, 5 minutes) 137 
and d) for CuSMHD [Cu(OAc)2·H2O, MeOH, 65°C, 1 hour], for CuSBHD [Cu(OAc)2, 138 
acetonitrile, r.t., 1 hour]. 139 
 140 
 141 
 142 
 143 
         144 
 145 
 146 
 147 
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2.2. Characterization of the complexes in the solid state 148 
The characteristic infrared band of the S-substituted dithiocarbazate ligand, ν(N-H) at 149 
ca. 3129 cm-1 and ν(C=S) at ca. 1050 cm-1 disappeared upon formation of the Cu(II) 150 
complexes confirming deprotonation of nitrogen to form the iminothiolate ion and its 151 
chelation through N and S. ν(C=N) of the azomethine bond shifted to lower energy (1611 cm-152 
1
 and 1606 cm-1 for CuSMHD and CuSBHD respectively. A second band due to ν(N=C) in 153 
complexes containing anionic dithiocarbazate moieties was also resolved [42]. The ligand 154 
hydrazinic band ν(N-N) at ca. 828 cm-1 also shifted upon complexation, to higher (CuSBHD) 155 
and lower (CuSMHD) wavenumbers. All these observations confirm deprotonation of the 156 
Schiff bases with coordination through the azomethine nitrogen atom. The ligand ν(CSS) 157 
band ca. 985 cm-1 split into two components at 1000-955 cm-1 upon complexation. The 158 
presence of this band and the absence of the C=S band in the spectra of the metal complexes 159 
provide additional evidence of the coordination of the Schiff base to the metal in its thiolate 160 
form [43, 44]. The complexes were also characterized by elemental microanalysis. The 161 
analytical data agree well with the formulations proposed for the complexes.  162 
 163 
Magnetic susceptibility values at room temperature for the CuSMHD and CuSBHD 164 
complexes were determined using a Sherwood Magnetic Susceptibility Balance-AUTO to be 165 
1.66 B.M and 1.48 B.M, respectively, as expected for paramagnetic 3d9 ions in a square-166 
planar environment (spin-only value 1.73 B.M) [44, 45]. The slightly low values observed 167 
can be attributed to interaction between Cu(II) ion centers [46, 47] 168 
 169 
As mentioned in synthesis and characterization, pyrrolyl derivative SBPY is a 170 
cyclisation product obtained during the attempted synthesis of SBHDH2. The molecular 171 
structure of SBPY is shown in Fig. 1a. In SBHDH2, the central CN2S2 chromophore is planar 172 
(r.m.s. = 0.0490 Å) and forms dihedral angles of 88.49(4) and 68.14(4)º with the pyrrolyl and 173 
phenyl rings, respectively. As the rings lie to the same of the molecule and opposite to the 174 
thione-S1 atom, the overall conformation is best described as being U-shaped. The dihedral 175 
angle between the rings is 60.874(6)º indicating a splayed relationship. The thione-S1 and 176 
amine-H atoms are syn which might be expected to lead to an eight-membered {…HNCS}2 177 
synthon in the crystal packing. Nevertheless, the most prominent feature of the crystal 178 
packing is the formation of N–H…pi (pyrrolyl) interactions, Fig. 1b, which lead to the 179 
formation of centrosymmetric dimeric aggregates. 180 
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 181 
 182 
Fig. 1. (a) The molecular structure of SBPY, showing atom-labelling scheme, and (b) 183 
supramolecular dimer sustained by N–H…pi (pyrrolyl) interactions. 184 
 185 
The molecular structure of SMHDH2 crystallises about a crystallographic centre of 186 
inversion located at the mid-point of the C3-C3i bond indicting the molecule has an anti 187 
disposition of the dithiocarbazate residues; symmetry operation i: 1-x, 2-y, 1-z. The 188 
conformation about the hydrazone bond is E. The entire molecule is planar with the r.m.s. for 189 
the 18 non-hydrogen atoms comprising the entire molecule being 0.038 Å, with the 190 
maximum deviations being ±0.061 Å for the S2 atom. 191 
 192 
 193 
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Fig. 2. (a) The molecular structure of SMHDH2, showing atom-labelling scheme. Unlabelled 194 
atoms are related by the symmetry operation 1-x, 2-y, 1-z, and (b) supramolecular chain 195 
mediated by N–H…S hydrogen bonds via centrosymmetric eight-membered {…HNCS}2 196 
synthons. [N1–H1n…S1 = 2.64(2) Å, N1…S1 = 3.455(2) Å, and angle at H1n = 156(3)º; 197 
symmetry operation i: 2-x, 2-y, 2-z] 198 
 199 
The doubly deprotonated SMHD species functions as a tetradentate N2S2 donor ligand 200 
in its complex with copper(II). The molecular structure of CuSMHD is shown in Fig. 3a and 201 
selected geometric bond lengths (Å) and angles (°) for this, CuSBHD and for SMHDH2 are 202 
collected in Table 1. To a first approximation, the seven-membered ring may be described as 203 
having a half-chair conformation where the C4 atom lies 0.9317(16) Å above the plane 204 
defined by the Cu, N2, N3, C2, C3 and C5 atoms; r.m.s. = 0.1373 Å with maximum 205 
deviations 0.1590(6) Å for Cu and -0.1595(10) Å for C2. The two five-membered chelate 206 
rings have similar conformations. The S1-containing ring is an envelope with the flap atom 207 
being the Cu atom which lies 0.7857(16) Å above the least-squares plane defined by the 208 
remaining four atoms (r.m.s. = 0.0119 Å). By contrast, the S3-containing ring is considerably 209 
more planar but is still described as having an envelope conformation with the Cu atom being 210 
the flap. In this description, the Cu atom lies 0.2103(18) Å out of the plane defined by the 211 
four remaining atoms which has a r.m.s. of 0.0043 Å. There is a clear distortion away from 212 
the ideal square planar geometry as is commonly observed in seven-membered rings having 213 
two hydrazone bonds [48]. In CuSMHD, the angle between the two five-membered chelate 214 
rings is 46.10(2)º, and the range of angles subtended at the Cu atom is 84.89(3)º for S1–Cu–215 
N2 to 164.90(4)º for S1–Cu–N3. 216 
 217 
 218 
Fig. 3. The molecular structure of CuSMHD, showing atom-labelling scheme. 219 
 220 
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The availability of the crystal structure of SMHDH2 enables a comparison of the 221 
geometric parameters in the free molecule and in its coordinated dianion in CuSMHD. Two 222 
quite distinct differences are noted in the bond lengths collected in Table 1. First and 223 
foremost, there has been a significant elongation, i.e. 0.08 Å, of the formally C1=S2 thione 224 
bond in SMHDH2 once this atom is complexed to Cu. Secondly, there has been a notable 225 
reduction, i.e. 0.05 Å, of the amine C1–N2 bond in SMHDH2, consistent with the formation 226 
of an imine bond in the complex. The reorganisation of electron density around the NCS2 227 
residue results in the contraction in the S–C–S angle with concomitant expansion in the 228 
angles involving the formally doubly bonded nitrogen atom, Table 1. In the crystal packing, 229 
molecules stack in columns aligned along the b-axis with no directional interactions between 230 
them. 231 
The molecular structure of CuSBHD, Fig. 4a and Table 1, shows the same features as 232 
just discussed for CuSMHD, consistent with the notion that the nature of the S-bound 233 
substituent, methyl or benzyl, does not exert a significant difference upon the structure. This 234 
observation is highlighted in the overlay diagram shown in Fig. 4b. The seven-membered 235 
ring in CuSBHD has a half-chair conformation with the C4 atom lying 0.9970(19) Å above 236 
the plane defined by the Cu, N2, N3, C2, C3 and C5 atoms; r.m.s. = 0.2078 Å with maximum 237 
deviations 0.2432(7) Å for Cu and -0.3012(10) Å for N3. The aforementioned parameters 238 
indicate that this chelate ring is more distorted in CuSBHD cf. CuSMHD. With respect to the 239 
two five-membered chelate rings, the S1-containing ring is an envelope with the flap atom 240 
being the Cu atom which lies 0.7703(19) Å above the least-squares plane defined by the 241 
remaining four atoms (r.m.s. = 0.0004 Å), as is the S3-chelate ring with the Cu atom lying 242 
0.423(2) Å above the plane of the four remaining atoms (r.m.s. = 0.0027 Å). In CuSBHD, the 243 
angle between the two five-membered chelate rings is 48.93(4)º, and the range of angles 244 
subtended at the Cu atom is 84.35(4)º for S3–Cu–N3 to 175.08(4)º for S1–Cu–N3, i.e. 245 
marginally broader than observed in CuSMHD, Table 1. 246 
 247 
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Fig. 4. (a) The molecular structure of CuSBHD, showing atom-labelling scheme, and (b) 248 
overlay diagram of CuSMHD (red image) and CuSBHD (blue). The complex molecules are 249 
overlapped so that the S1, Cu and S3 atoms are coincident. 250 
 251 
The crystal packing of CuSBHD also resembles that of CuSMHD in that columns of 252 
molecules are evident, aligned along the a-axis. However, in CuSBHD molecules are linked 253 
by a combination of C–H…S and C–H…pi (phenyl) interactions. Geometric parameters 254 
characterising the intermolecular interactions operating in the crystal structure of CuSBHD: 255 
C4–H4a...S4i = 2.83 Å, C4...S4i = 3.7647(16) Å, and angle at H4a = 158º for i: -x, -½+y, -½-256 
z; C4–H4b...S3ii = 2.84 Å, C4...S3ii = 3.6946(19) Å, and angle at H4b = 145º for ii: -x, 1-y, -257 
z; C18–H18...S4iii = 2.86 Å, C18...S4iii = 3.6811(17) Å, and angle at H18 = 145º for iii: x, 258 
1½-y, -½+z; C3–H3a...Cg(C17–C22)i = 2.89 Å, C3...Cg(C17–C22)i = 3.6538(17) Å, and 259 
angle at H3a = 135º. 260 
 261 
 The observed four-coordinate structures described here for CuSBHD and CuSMHD, 262 
with the dianions in the iminothiolate form, is consistent with literature precedents [15, 16, 263 
48-51]. 264 
  265 
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Table 1 266 
Selected geometric parameters (Å, º) for SMHDH2, CuSMHD and CuSBHD. 267 
___________________________________________________________________________ 268 
Compound SMHDH2 CuSMHD CuSBHD 269 
___________________________________________________________________________ 270 
Parameter 271 
Cu–S1 – 2.2480(4) 2.2458(4) 272 
Cu–S3 – 2.2523(4) 2.2659(4) 273 
Cu–N2 – 2.0555(12) 2.0704(13) 274 
Cu–N3 – 1.9792(12) 1.9927(14) 275 
C1–S1, S2 1.655(3), 1.763(3) 1.7373(14), 1.7579(14) 1.7354(16), 1.7573(17) 276 
C6–S3, S4 – 1.7380(14), 1.7533(14) 1.7404(16), 1.7560(16) 277 
N1–C1, N2–C2 1.339(3), 1.281(3) 1.2892(19), 1.2914(18) 1.286(2), 1.292(2) 278 
N1–N2 1.391(3) 1.4182(16) 1.4181(18) 279 
C5–N3, C6–N4 – 1.2872(18), 1.2887(18) 1.285(2), 1.286(2) 280 
N3–N4 – 1.4073(16) 1.4019(18) 281 
S1–Cu–S3 – 92.795(14) 91.655(15) 282 
S1–Cu–N2 – 84.89(3) 85.26(4) 283 
S1–Cu–N3 – 164.90(4) 175.08(4) 284 
S3–Cu–N2 – 148.04(3) 148.89(4) 285 
S3–Cu–N3 – 85.76(4) 84.35(4) 286 
N2–Cu–N3 – 104.21(5) 99.65(5) 287 
C1–N1–N2 119.2(2) 113.22(11) 113.38(12) 288 
C2–N2–N1 117.0(2) 112.01(11) 112.92(13) 289 
C5–N3–N4 – 115.20(11) 115.88(13) 290 
C6–N4–N3 – 112.83(11) 112.70(12) 291 
 292 
S1–C1–S2 123.83(16) 113.87(8) 111.63(9) 293 
N1–C1–S1 122.7(2) 127.49(11) 128.34(13) 294 
N1–C1–S2 113.51(18) 118.63(11) 120.01(12) 295 
S3–C6–S4 – 113.94(8) 113.16(9) 296 
N4–C6–S3 – 127.17(11) 126.59(12) 297 
N4–C6–S4 – 118.89(10) 120.23(12) 298 
___________________________________________________________________________ 299 
 300 
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Table 2 301 
Crystallographic and refinement details for SBPY, SMHDH2, CuSMHD and CuSBHD. 302 
Compound SBPY SMHDH2 CuSMHD CuSBHD 303 
Formula C14H16N2S2 C10H18N4S4 C10H16CuN4S4 C22H24CuN4S4 304 
Formula weight 276.41 322.52 384.05 536.23 305 
Crystal colour/habit Colourless plate Yellow needle Black prism Black prism 306 
Crystal dimensions/mm 0.04 x 0.20 x 0.21 0.03 x 0.06 x 0.24 0.04 x 0.12 x 0.18 0.11 x 0.22 x 0.28 307 
Crystal system monoclinic triclinic monoclinic monoclinic 308 
Space group P21/c P¯1 C2/c P21/c 309 
a/Å 9.2991(4) 5.1646(5) 24.6441(8) 10.7937(1) 310 
b/Å 15.9635(8) 7.2792(8) 7.9100(2) 18.8337(2) 311 
c/Å 9.4848(5) 10.7840(12) 16.8972(6) 11.8412(2) 312 
α/° 90 100.652(9) 90 90 313 
β/° 96.155(1) 90.751(9) 111.167(4) 103.410(1) 314 
γ/° 90 107.305(10) 90 90 315 
V/Å3 1399.87(12) 379.39(7) 3071.62(18) 2341.51(5) 316 
Z 4 1 8 4 317 
Dc/g cm-3 1.312 1.412 1.661 1.521 318 
F(000) 584 170 1576 1108 319 
μ/mm-1 0.364 5.662 1.956 1.308 320 
Measured data 19199 4869 19072 58909 321 
Radiation MoKα CuKα MoKα MoKα 322 
θ range/° 2.5–27.5 4.2–71.6 2.6–27.5 2.2–27.5 323 
Unique data 3207 1455 3490 5353 324 
Observed data (I ≥ 2.0σ(I)) 2722 1197 3291 4827 325 
R, obs. data; all data 0.032; 0.041 0.046; 0.055 0.019, 0.021 0.028, 0.032 326 
a, b in weighting scheme 0.030, 0.621 0.078, 0.048 0.032, 2.432 0.050, 1.156 327 
Rw, obs. data; all data 0.071; 0.075 0.121; 0.130 0.054, 0.055 0.077, 0.080 328 
Residual electron density 329 
peaks/e Å3 0.30, -0.26 0.43, -0.28 0.37, -0.31 0.67, -0.47 330 
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2.3. Solution characterization of the complexes 331 
The UV-Vis absorption spectra of the compounds for 25 μM and 1 mM solutions 332 
(inset) in DMSO are shown in Figure 5. Both complexes showed π→π* and n→π* intra-333 
ligand transitions at ca. 272 nm, 295 nm and 338 nm and a d-d band at approximately 600 nm 334 
that can be attributed to Jahn-Teller distortion from square planar geometry [47]. Copper(II) 335 
complexes of thiosemicarbazone and dithiocarbazate ligands generally exhibit a S→Cu(II) 336 
charge-transfer band at ~400 nm. The presence of this LMCT band in the spectra of the metal 337 
complexes is strong evidence that the metal ion is coordinated to sulphur [43, 52]. 338 
 339 
 340 
Fig. 5. UV-Vis spectra recorded at 25 μM in DMSO using a cell length of 1 cm. The insert 341 
shows the d-d band of the two complexes at concentration of 1 mM. 342 
 343 
The stability of the ligands and their corresponding complexes at physiological pH are 344 
important prerequisites for the evaluation of their biological activity. The molar conductance 345 
readings for the complexes in DMSO were in the range 12-13 Ω−1 cm2 mol−1, indicating that 346 
there is essentially no dissociation in that solvent [53]. To more precisely evaluate their 347 
stability, reverse phase HPLC experiments have been performed. The ligands and their 348 
complexes were eluted on a C18-column with an increasing amount of CH3CN in H2O (from 349 
5% to 100% of CH3CN over 30 minutes), containing 0.1 % TFA to maintain pH. The 350 
compounds were detected using a UV lamp at 220 nm and 280 nm. The chromatograms of 351 
the pure ligands showed three peaks that could correspond to the hydrolyzed hydrazone, the 352 
expected ligand and the pyrrole byproduct whereas the complexes showed only the single 353 
peak of the copper complexes (see Supplementary Data). It is noteworthy that the hydrazone 354 
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bond stability is significantly increased upon metal-complexation under acidic conditions 355 
suggesting that complexation could be used as a means to protect the ligand from degradation 356 
that might occur in biological systems before free ligand could reach its target. 357 
 358 
2.4. Electron Paramagnetic Resonance (EPR)  359 
The EPR spectra recorded in DMF shown in Figure 6 are typical of Cu(II) complexes 360 
having axial symmetry and distorted square planar geometry with the unpaired electron 361 
mainly in the dx2 - dy2 orbital. The spectra also exhibit partially resolved superhyperfine 362 
features. The g∥ values for all the complexes are similar to those previously reported for 363 
analogous Cu(II)N2S2 complexes [16, 25, 54]. Kivelson and Nieman [55, 56] suggested that 364 
g|| values higher than 2.3 are indicative of a predominantly ionic character for metal-ligand 365 
bonds, whereas g|| values smaller than 2.3 reveal metal-ligand bonds of predominantly 366 
covalent character, as is the case here (see Table 3). In addition, the relatively small g∥ value 367 
(g∥ ~2.20) suggests a strong nitrogen character in the singly occupied molecular orbital. EPR 368 
spectroscopy is sensitive to angular distortions at the Cu(II) centre, particularly those 369 
involving distortions from planar to tetrahedral geometry. As a general rule, distortion from 370 
planar towards tetrahedral geometry results in a decrease in A∥ and an increase in g∥ [52]. The 371 
empirical factor f (= g||/Α||) [57, 58] is a measure of deviation from idealized geometry. Its 372 
value ranges between 105 and 135 cm for square planar complexes, depending on the nature 373 
of coordinated atoms, while, for tetrahedral structures, values from 160 to 242 cm suggest a 374 
moderate to considerable tetrahedral distortion. CuSBHD displays a slightly higher degree of 375 
tetrahedral distortion than CuSMHD in solution similar to their structures in solid. They are 376 
also slightly more distorted compared to some analogues, probably due to their extended 377 
carbon backbones [16, 25, 54]. Molecular orbital coefficients, α2 (in-plane σ-bonding), were 378 
calculated using the equation below:  [42, 59]  379 
α2 = (A∥ / 0.036) + (g∥ − 2.0036) + 3 / 7 (g⊥ − 2.0036) + 0.04 380 
An α2 value of 0.5 indicates complete covalent bonding, while 1.0 suggests complete ionic 381 
bonding. The observed value of 0.64 for the present complexes indicates that these copper 382 
complexes have some covalent character, as suggested above.  383 
 384 
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 385 
Fig. 6. EPR spectra of CuSBHD in black and CuSMHD in red recorded at a microwave 386 
frequency 9.50 GHz, power 0.25 mW, modulation amplitude 0.2 mT, modulation frequency 387 
100 kHz, and time constant 164 ms, at 50 K. Samples were prepared in DMF (1 mM). 388 
 389 
Table 3 390 
EPR parameters measured from the spectra of the copper(II) complexes in DMF.  391 
 g|| g⊥ Α||[a] f[b] α2 
CuSMHD 2.15 2.06 460 (153) 141 0.64 
CuSBHD 2.16 2.06 451 (150) 143 0.64 
[a] Unit in MHz, in bracket = Α|| x 10-4 cm-1 [b] cm. 392 
 393 
2.5. Electrochemistry 394 
As redox properties have been linked to SOD and anticancer properties of metal 395 
complexes [60, 61], we describe herein the electrochemical properties of Cu(II) bis(dithio 396 
carbazate). Figure 7 shows the profile of the Cu(II) complexes obtained with SMHDH2 and 397 
SBHDH2 at scan rate 100 mV s−1. Both complexes undergo an electrochemically irreversible 398 
one-electron reduction at Epc = -0.328 and -0.285 V/(AgCl/Ag and Fc+/Fc = 0.563 V), 399 
respectively, coupled with oxidation at Epa = 0.069 and 0.129 V/(AgCl/Ag). These waves can 400 
be assigned to the irreversible oxidation/reduction of Cu(II)/Cu(I) [51]. The redox properties 401 
of the ligands were found to be innocent. The irreversible nature of the copper-centered redox 402 
waves contrasts with the quasi-reversible reduction previously reported for the CuATSM and 403 
CuAATSM analogues [49, 50]. The loss of reversibility observed in this work is most likely 404 
related to differences in the geometric rearrangement about the Cu(II)/Cu(I) ions in this 405 
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ligand system that possesses two carbons between the two hydrazone functions. The 406 
Cu(II)/Cu(I) redox potentials of CuSMHD and CuSBHD are also more positive than the 407 
previous examples. The ease of deformation seems to favour reduction. The difference in 408 
redox potential between CuSMHD and CuSBHD can be due to changes in inductive effects 409 
of the substituents. The increase in Cu redox potentials resulting from altering the terminal S-410 
substituent (from methyl to benzyl) can be rationalized by the stronger electron-donating 411 
effect of the methyl group [62]. 412 
 413 
As mentioned above, the oxidation proceeding at higher positive potential has 414 
previously been assigned to the copper(III/II) redox couple. It is interesting to note the 415 
occurrence of an additional peak, which can be attributed to the reduction of a species 416 
produced by the second oxidation. However, the nature of this oxidized complex has not been 417 
determined. 418 
 419 
 420 
Fig. 7. Cyclic voltammograms of the Cu complexes at 1.7 mM in anhydrous deoxygenated 421 
DMF containing 0.1 M tetrabutylammonium hexafluorophosphate as the supporting 422 
electrolyte. Working electrode: glassy carbon; counter electrode: Pt wire; reference electrode: 423 
AgCl/Ag, scan rate: 100 mV/s. All sweeps were initiated in the direction of the arrow. 424 
Table 4 425 
Electrochemical data for CuSMHD and CuSBHD versus AgCl/Ag. 426 
 Cu(II)/Cu(I) Cu(III)/Cu(II) 
 
Epc/V Epa/V Epc/V Epa/V 
CuSMHD -0.328 0.069 0.195 0.899 
CuSBHD -0.285 0.129 0.357 0.870 
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3. Biological evaluation 427 
3.1. Antibacterial activity 428 
The free Schiff base ligands and their metal complexes were tested for their ability to 429 
inhibit the growth of ten strains of Gram-negative and Gram-positive bacteria (Table 5). The 430 
effects of a membrane permeabilizing agent and efflux pumps were investigated in an attempt 431 
to correlate the activity of the compounds with their penetration of the bacteria and the 432 
resistance mechanisms of the bacteria. 433 
 434 
One of the limitations of this class of compounds is their poor solubility in aqueous 435 
solution particularly at high concentration to make stock solutions. The universal solvent 436 
DMSO has often been used in many studies to pre-dissolve the compounds for biological 437 
assays. However, it has been shown that DMSO solutions (1% to 10%) considerably affect 438 
the growth of fungi and cancerous cells, and, at 15%, DMSO effectively eliminates the 439 
growth of certain bacteria [63-65]. DMSO has also been reported to enhance permeability of 440 
the lipid membrane as well as to cause cell membranes to become less rigid facilitating 441 
membrane diffusion of exogenous species [66-69]. As DMSO is used in this work to 442 
encourage dissolution of the compounds and there is no rule of thumb on the amount of 443 
DMSO to be used for antibacterial assay, we feel the need to examine the influence of DMSO 444 
concentrations on the growth curve of the selected bacteria strains. The minimum inhibition 445 
concentration (MIC) values were determined in presence of DMSO at 0.5% and 5% (v:v) of 446 
DMSO. We found that the growth of bacteria strains A. baumannii and P. aeroginosa is 447 
inhibited by DMSO at a concentration of only 5% thus preventing determination of MIC 448 
under this condition. The growth of bacteria E. coli and E. aerogenes (see Supplementary 449 
Data) was also affected by the DMSO at 5%. Differences were observed between MIC values 450 
against the mutated strains E. coli AcrAB- and E. aerogenes 298 TolC- obtained in the 451 
presence of 0.5% or 5% DMSO for certain molecules, in particular, CuSMHD. Additional 452 
MIC values determined for CuSMHD using DMSO 50%, 30% and 20% (2.5%, 1.5% and 1% 453 
final v:v DMSO) were all higher than 128 µM while with 5% of DMSO, the MIC value was 454 
in the range of 1-2 and 0.5-1 µM against those two strains, respectively. Because of the effect 455 
of DMSO on bacterial growth, we are unable to confirm that the value truly reflects the 456 
specific antimicrobial activity of the compound alone. It could correspond to a synergetic 457 
effect involving the compound and DMSO. Since 0.5% DMSO has shown not to interfere 458 
with bacterial growth, the MIC values recorded using this concentration should indeed be 459 
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valid and are therefore used for discussion of the role of membrane permeabilizing agents and 460 
efflux pumps. 461 
 462 
As it has been reported that low permeability of the outer membrane and the efficiency 463 
of efflux pumps [3, 4] are prime factors limiting intracellular activity of potential 464 
antimicrobial compounds, it is expected that the presence of a substance known to increase 465 
membrane permeability, such as polymyxin B nonapeptide (PMBN) [70], would act 466 
synergistically with the studied compounds to promote their antimicrobial efficiency by 467 
facilitating an increase in their uptake. The compounds were tested in the presence and 468 
absence of sub-inhibitory concentrations (1/5 of its direct MIC value) of PMBN. In the 469 
absence of PMBN none of the compounds except for SMHDH2 was active against the strains 470 
tested (MIC ≥ 64 µM). SMHDH2 showed moderate activity against S. aureus. However, up 471 
to 3-fold improvement in activity (MIC values) was observed for the organic compounds 472 
SMHDH2, SBHDH2 and SBDP in the presence of PMBN against both Gram-negative and 473 
Gram-positive bacteria. These results strongly suggest that the compounds apparent lack of 474 
activity was due to their inability to efficiently penetrate the bacteria membrane. Among the 475 
compounds, the Schiff base SMHDH2 showed a broad range of moderate activity against 476 
various strains with the most promising MIC values at or around 16 µM against E. coli 477 
AcrAB-, A. baumannii, P. aeroginosa and S. aureus, thus making it a potential antimicrobial 478 
agent in the presence of PMBN. It is known that the biological activity of dithiocarbazate 479 
compounds can be greatly modified by the presence of different substituents. For instance, 480 
inhibition of E. coli and S. aureus by the Schiff base prepared from 2-benzoylpyridine with 481 
S-methyldithiocarbazate (SMDTC) is highly effective whereas that of the 482 
S-benzyldithiocarbazate (SBDTC) analog shows no activity [71]. The better activity for 483 
SMDTC-derived SMHDH2 observed compared to SBDTC derivative is consistent with the 484 
previous report. 485 
 486 
 487 
   488 
  489 
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Table 5  490 
Antibacterial activity of the tetradentate series. 491 
 492 
 493 
Colour code: MIC values or average MIC values ≥ 64 µM = red, ≤10 µM = green, in between 64 µM and 10 µM = colourless.  MIC values 494 
higher than 64 µM indicate poor activity.  495 
 Minimum Inhibitory Concentration (MIC)  (µM) 
Compound Gram- Gram+ 
 E. coli E. aerogenes A. baumannii 
K.  
pneumoniae 
P. 
aeruginosa 
S.  
enterica S. aureus 
 
AG100 
WT 
AG100A 
AcrAB- 
EA289 
 AcrAB+ 
EA298 
 TolC- 
ATCC 
19606 
ATCC  
11296 PA01 SL696 SA1199 
% DMSO 0.5 5 0.5 5 0.5 5 0.5 5 0.5 0.5 5 0.5 0.5 5 0.5 5 
SMHDH2 >128 >128 >128 >128 >128 128-64 >128-128 >128 64 128 64 128-64 >128 >128 32 64-32 
+PMBN 32 32 16 16 >128-128 64 128 32 16 64 32-16 16-8 64 32 32-16 64-32 
CuSMHD >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
+PMBN >128 >128 >128 1-2 >128 >128 >128-128 0.5-1 >128 >128 >128 >128 >128 >128 >128 >128 
SBHDH2 >128 128 >128 128 >128 128-64 >128-128 64 >128 >128 128 >128 >128 >128 >128 64-32 
+PMBN >128 64 128-32 32-16 >128-128 64 
>128-
64 16-4 128-64 128-64 32-16 64-32 >128 64 16 128 
CuSBHD >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
+PMBN >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
SBPY >64 >64 >64 >64 >64 >64 >64 >64 >128 >128 >128 >128 >128 >128 128 128-64 
+PMBN 64 64 32 16 >64 64 32 4 >128-128 >128 64 >128-128 64 64-32 128-64 128 
Cu(Ac)2 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
+PMBN >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
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The role of efflux pumps was investigated using pump-deleted strains of Gram-negative 496 
E. coli and E. aerogenes. Both SMHDH2 and SBPY seemed more active (16 µM and 32 µM, 497 
respectively) towards the isogenic derived strain, in which the efflux pump AcrAB genes are 498 
deleted as compared to wild-type E. coli (64 µM). No significant activity was observed for 499 
SMHDH2 in the absence likewise in presence of efflux pump for E. aerogenes. SBPY on the 500 
other hand showed differences in the MDR clinical isolate EA289 overexpressing the AcrAB 501 
efflux pump and on its efflux negative TolC- derivative EA298 with improvement in MIC 502 
from > 64 µM to 32 µM. These results confirmed that SBPY and SMHDH2 are recognized 503 
by the efflux pumps and expelled from the bacteria thus limiting their bioactivity. Both 504 
SMHDH2 and SBHDH2 showed activity towards Gram-positive S. aureus. Typically, 505 
antibacterial molecules are more active toward Gram-positive than Gram-negative bacteria 506 
[72, 73], as the additional outer membrane of the latter organisms impairs or slows down the 507 
drug uptake. It has often been reported in the literature that bioactivity of a ligand is enhanced 508 
by metal complexation [48, 57], but in our case, the formation of the copper complexes 509 
induces a loss of antibacterial potency of the compounds. Similar loss in activities were 510 
previously reported with palladium(II) and platinum(II) complexes with acetone Schiff bases 511 
[7]. This can be explained by a lower solubility of the metal complexes or by the lower 512 
stability of the hydrazone moiety in the case of the free ligands, as seen above. As mentioned 513 
before, depending on the pH, the ligands can be hydrolyzed in aqueous solution leading to 514 
several reactive products that can interfere with the bacteria constituents and be responsible 515 
for the toxicity. At this stage it is not possible to conclude but the positive effects of high 516 
DMSO concentration on the one hand, and of PMBN on the other, strongly suggest that 517 
improvements can be expected by increasing the solubility and bacteria penetration. Efforts 518 
are currently ongoing to significantly improve the aqueous solubility. 519 
 520 
3.2. Cytotoxic assay 521 
The cytotoxicity of the ligands and complexes was evaluated in vitro against two 522 
breast cancer cell lines MDA-MB-231 (human breast carcinoma cells not expressing nuclear 523 
estrogen receptors) and MCF-7 (human breast carcinoma cells expressing nuclear estrogen 524 
receptors). Measurement of the cytotoxicity was carried out using MTT assay [74] based on 525 
the metabolic reduction of tetrazolium salt to form water insoluble formazan crystals, with 526 
tamoxifen as standard. DMSO was used as negative control in the assay and the final content 527 
of DMSO for each compound tested was ≤ 0.5%.  There was no perceptible precipitation of 528 
21 
 
the compounds. The concentrations required to inhibit the growth of cancer cells by 50% 529 
(IC50) are shown in Table 6. 530 
Table 6 531 
Cytotoxic assay results.  532 
 IC50 (μM) 
 MCF-7 MDA-MB-231 
SMHDH2 138.90  9.61 
SBHDH2 9.69 1.05 
CuSMHD 2.60 2.34 
CuSBHD 1.49 0.71 
Tamoxifen  11.20 13.40 
 533 
Both ligands displayed at least 9-fold better toxicity towards the MDA-MB-231 cell line 534 
that does not express estrogen nuclear receptors, indicating that ligand toxicity is not only 535 
mediated by these receptors. SBHDH2 exhibits a stronger toxicity, which could be related to 536 
its comparatively higher lipophilicity that may facilitate diffusion into cells [12]. 537 
Complexation of the Schiff base ligands with copper(II) has been found to produce 538 
synergistic effects on the antiproliferative activities of  some parent ligands [75] and here the 539 
complexes showed a marked cytotoxicity with IC50 values < 5.0 µM towards both cell lines. 540 
Like the ligands, the complexes are also more active towards MDA-MB-231 cells, suggesting 541 
that their toxicity does not involve estrogen receptors. For both cell lines, the benzyl 542 
substituted complex CuSBHD showed slightly higher IC50 values. A clear structure-activity 543 
relationship cannot be deduced from the limited number of compounds tested, however, the 544 
stronger activity of CuSBHD could also be linked with its higher cellular uptake due to its 545 
increased lipophilicity as suggested above for the ligand. Alternatively, its higher redox 546 
potential could be a discriminating factor, since a higher redox potential means that Cu(II) 547 
reduction is easier, and consequently a higher content of Cu(I) could be generated. Cu(I) is 548 
prone to participate in Fenton-type reactions that produce reactive oxygen species (ROS), 549 
which can damage biomolecules within cells [61]. 550 
 551 
4. Conclusions  552 
In conclusion, we have gained new insight into the structural, electrochemical and 553 
biological aspects of macroacyclic Cu(II) complexes derived from S-substituted 554 
dithiocarbazate. All the compounds exhibited good cytotoxicity towards breast cancer cells. 555 
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The poor antimicrobial activity can be related to their poor bacterial penetration and poor 556 
solubility which should be amenable to improvement. The fact that the anticancer activity 557 
Cu(II) complexes are more efficient than the ligands is interesting. By expanding the carbon 558 
backbone between the hydrazone moities, the compounds showed further distortion from 559 
square planar geometry in both solution and in the solid state and a positive shift in the 560 
Cu(II)/Cu(I) reduction potential. A higher reduction potential could be related to the 561 
promising bioactivity observed in this present work. Taking into consideration the serious 562 
side effects and the poor efficacy of clinical reference drugs, as well as the appearance of 563 
resistance during treatment, these complexes are potentially useful lead candidates for the 564 
development of new therapeutic agents to treat cancer and bacterial infections. In addition, 565 
we outlined in this paper the need to take into consideration the concentration of DMSO used 566 
to dissolve the compounds, since DMSO may act synergistically with the compounds tested. 567 
The lack of uptake of the compounds due to low permeability of the outer membrane and the 568 
efficiency of efflux pumps were also shown to be issues to be addressed in subsequent 569 
studies. With these considerations in mind, our group is attempting to improve antimicrobial 570 
and anticancer activities of compounds in this family by exploring the design and synthesis of 571 
a new generation of S-substituted dithiocarbazate derivatives and their metal complexes that 572 
will be more water-soluble, that may be better able to penetrate cell membranes and escape 573 
from the efflux pump.  574 
5. Experimental 575 
5.1. Materials-instrumentation-physical measurements 576 
All chemicals and solvents were of analytical grade and were used as received. 577 
Chemicals: Potassium hydroxide (Merck), hydrazinium hydroxide (Merck), carbon disulfide 578 
(Sigma Aldrich), 2,5-hexanedione (Merck), and copper(II) acetate monohydrate (Analar). 579 
The IR spectra were recorded in the range of 550-4000 cm−1 on a Perkin-Elmer 100 series 580 
FT-IR spectrophotometer in ATR mode. Magnetic susceptibility was measured with a 581 
Sherwood MSB-AUTO at room temperature. All susceptibilities were corrected for the 582 
diamagnetic contribution using Pascal’s constant. Microanalyses were carried out using either 583 
a Leco CHNS-932 analyzer or performed at the CNRS (Gif-sur-Yvette and Vernaison, 584 
France). The molar conductance of a 10-3 M solution of each metal complex in DMSO was 585 
measured at 29°C using a Jenway 4310 conductivity meter and a dip-type cell with platinized 586 
electrode. The UV-Vis spectra were recorded on a Cary 300 bio spectrophotometer (200-800 587 
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nm) or Perkin Elmer Lambda 45 with a 1 cm optical path quartz cuvette. 1H NMR and 13C 588 
NMR spectra were recorded with Bruker DRX300 spectrometers. The chemical shifts 589 
(δ/ppm) were calibrated relative to residual solvent signals. Electrospray-ionization mass 590 
spectra (ESI-MS) were recorded with a Finnigan Mat 95S in the BE configuration at low 591 
resolution. Electron paramagnetic resonance (EPR) spectra were recorded on an X-band 592 
Bruker Elexsys 500 spectrometer equipped with a continuous flow helium cryostat (Oxford 593 
Instruments) and a temperature control system. The field modulation frequency was 100 kHz. 594 
The spectra were all recorded under nonsaturating conditions. Cyclic voltammetry (CV) 595 
measurements were recorded under argon using a 620C electrochemical analyzer (CH 596 
Instruments, Inc). The working electrode was a glassy carbon disk; a Pt wire was used as 597 
counter electrode and the reference electrode was an AgCl/Ag electrode. Immediately before 598 
the measurement of each voltammogram, the working electrode was carefully polished with 599 
alumina suspensions (1, 0.3 and 0.05 μm, successively), sonicated in an ethanol bath and then 600 
washed carefully with ethanol. The solutions were made up with 100 µL solutions of the 601 
complexes (0.01 M) in anhydrous deoxygenated DMF with 0.5 mL of tetrabutylammonium 602 
hexafluorophosphate (0.1 M) as the supporting electrolyte (total volume is 0.6 mL).  603 
Ferrocene was used as an internal reference for which the ferrocinium/ferrocene one-electron 604 
redox process occurs at E1/2 = 0.51 V (DMF) vs AgCl/Ag with scan rate = 0.1 V/s. RP-HPLC 605 
analysis was carried out using Waters HPLC system connected to Breeze software that 606 
consisted of combination of a dual wavelength UV-Vis absorbance detector (Waters 2487) 607 
and a binary pump (Waters 1525) equipped with an analytical cell for reaction monitoring or 608 
purity checking. The analytical measurements were performed using an ACE C18 column 609 
(250 × 4.5mm) packed with spherical 5 µm particles of 300 Å pore size. Experiments were 610 
carried out at a flow rate of 1 mL  min-1 at room temperature. Injection volume was 50 µL. 611 
Sample concentration was approximately 1 mg mL-1. 612 
 613 
5.2. Preparation of ligands and metal complexes 614 
5.2.1 Synthesis of SBHDH2 615 
The title compound was synthesized with some modification of the method described 616 
by Ali et al. [35]. 2,5-hexandione (0.587 mL, 0.005 mol, 1 equiv.) was added to a hot 617 
solution of S-benzyldithiocarbazate (1.983 g, 0.01 mol, 2 equiv.) in absolute ethanol (150 618 
mL) and the mixture was further heated for 5 min. A white precipitate was formed and was 619 
immediately filtered off, washed with cold ethanol and dried in vacuo over silica gel to yield 620 
the expected Schiff base (0.997 g, Yield = 42%). Elemental analysis for C22H26N4S4: Calcd. 621 
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C 55.66, H 5.52, N 11.80; Found C 54.79, H 5.59, N 11.75.  1H NMR (300 MHz, DMSO-d6) 622 
δ 12.18 (s, 2H), 7.39 -7.20 (m, 10H), 4.40 (s, 4H), 1.96 (s, 6H). 13C NMR (75 MHz, DMSO-623 
d6) δ 197.16, 158.26, 137.15, 129.15, 128.41, 127.05, 37.56, 34.05, 17.74. IR: ν (cm-1) = 624 
3147 (m, b), 1640 (w), 1054 (s), 981 (m), 828 (m). UV-Vis in DMSO: λmax nm (log ε in 625 
L mol–1 cm–1) = 276 (4.32), 308 (4.41), ≈360 (3.32, sh). RP-HPLC: RT (min) = 15.3, 18.3, 626 
22.4. Molar conductivity:  Λ (ohm-1cm2mol-1) = 6.86. 627 
 628 
5.2.2 Synthesis of SMHDH2 629 
S-methyldithiocarbazate, SMDTC (1.222 g, 0.01 mol, 2 equiv.) was dissolved in hot 630 
ethanol (150 mL) and 2,5-hexandione (0.587 mL, 0.005 mol, 1 equiv.) was added to this 631 
solution. The mixture was heated while being stirred to reduce the volume to half. The 632 
mixture was kept at 4°C overnight and white precipitate was formed. The product was 633 
filtered off, washed with cold ethanol and dried in vacuo over silica gel to afford 1.129 g of 634 
SMHDH2 (Yield = 70%). The compound was further recrystallised from methanol and 635 
crystals suitable for X-ray diffraction analysis were obtained from the same solvent. 636 
Elemental analysis for C10H18N4S4: Calcd. C 37.24, H 5.63, N 17.37; Found C 37.86, H 4.87, 637 
N 17.84. 1H NMR (300 MHz, DMSO-d6) δ 12.13 (s, 2H), 2.57 (s, 4H), 2.43 (s, 6H), 2.00 (s, 638 
6H). 13C NMR (75 MHz, DMSO-d6) δ 198.95, 157.63, 33.97, 17.77, 16.94. IR: ν (cm–1) = 639 
3111 (m, b), 1628 (m), 1046 (s), 988 (m), 827 (m).  UV-Vis in DMSO: λmax nm (log ε in 640 
L mol–1 cm–1) = 276 (4.25), 305 (4.37), ≈360 (2.75, sh). RP-HPLC: RT (min) = 6.4, 11.1, 641 
18.7. Molar conductivity:  Λ (ohm-1cm2mol-1) = 3.58 642 
 643 
5.2.3. Synthesis of CuSBHD  644 
The copper complex was prepared by adding copper (II) acetate monohydrate (0.020 645 
g, 0.0001 mol, 1 equiv.) in acetonitrile (20 mL) to a solution of SBHDH2 (0.047 g, 0.0001 646 
mol, 1 equiv.) in acetonitrile (150 mL) at room temperature. The solution was stirred for an 647 
hour and then concentrated to reduce volume before being placed at 4°C overnight. The 648 
product was filtered off and recrystallised from acetonitrile to yield 0.039 g (Yield = 73%). 649 
Black crystals of diffraction quality were crystallized from acetonitrile after several days 650 
through slow evaporation at 4°C. Elemental analysis for C22H25CuN4S4: Calcd. C 49.27, H 651 
4.51, N 11.85; Found C 49.40, H 4.63, N 10.46. ESI-MS: m/z = [M+H]+ Calcd. 536.04, 652 
Found 536.02; [M+Na]+ Calcd. 558.02, Found 558.01; [M+K]+ Calcd. 573.99, Found 573.98; 653 
[2M+3H]+ Calcd. 1073.08, Found 1073.04. IR: ν (cm–1) = 1629 (m), 1606 (w), 992 (s), 955 654 
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(s), 857 (m). UV-Vis in DMSO: λmax nm (log ε in L mol–1 cm–1) = 275 (4.37), ≈294 (4.26, sh), 655 
≈340 (4.01, sh), ≈400 (3.55, sh), ≈600 (2.45, sh). RP-HPLC: RT (min) = 28.5. Magnetic 656 
moment: μ (B.M.) = 1.48. Molar conductivity:  Λ (ohm-1cm2mol-1) = 13.01.  657 
 658 
5.2.4. Synthesis of CuSMHD  659 
The copper complex was prepared by adding copper (II) acetate monohydrate (0.200 660 
g, 0.001 mol, 1 equiv.) in methanol (20 mL) to a hot solution of the above SMHDH2 (0.322 661 
g, 0.001 mol, 1 equiv.) in methanol (100 mL). The reaction was heated until the volume 662 
reduced to half and then placed at 4°C overnight. The product, which formed, was filtered off 663 
and recrystallised from acetonitrile to afford 0.296 g of CuSMHD (Yield = 77%). Black 664 
crystals of diffraction quality crystallized from acetonitrile after several weeks through slow 665 
evaporation at room temperature. Elemental analysis for: C10H17CuN4S4: Calcd. C 31.27, H 666 
4.20, N 14.59; Found C 31.35, H 4.24, N 14.64. ESI-MS: m/z = [M + H]+ Calcd. 383.97, 667 
Found 383.96; [M+Na]+ Calcd. 405.96, Found 405.94; [M+K]+ Calcd. 421.93, Found 421.92. 668 
IR: ν (cm–1) = 1628 (m), 1611(w), 1000 (s), 964 (s), 821 (m). UV-Vis in DMSO: λmax nm (log 669 
ε in L mol–1 cm–1) = 273 (4.34), ≈294 (4.24, sh), ≈340 (3.99, sh), ≈400 (3.49, sh) ≈600 (2.43, 670 
sh). RP-HPLC: RT (min) = 23.3. Magnetic moment: μ (B.M.) = 1.66. Molar conductivity:  Λ 671 
(ohm-1cm2mol-1) = 12.80.  672 
 673 
5.2.5. Synthesis of SBPY  674 
SBPY was a side product from the initial attempt to synthesize SBHDH2. Prolonged 675 
heating and purification via column chromatography caused the desired compound to 676 
undergo cyclization forming a pyrrole. Single crystals of diffraction quality were obtained 677 
from DMSO and analyzed by single crystal X-ray diffraction. ESI-MS: m/z = [M + H]+ 678 
Calcd. 277.08, Found 277.08; [M + Na]+ Calcd. 299.07, Found 299.06. 1H NMR (300 MHz, 679 
DMSO-d6): δ (ppm) = 12.29 (s, 1H), 7.45 – 7.20 (m, 5H), 5.69 (s, 2H), 4.45 (s, 2H), 2.00 (s, 680 
6H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) = 204.09, 136.30, 129.02, 128.55, 127.43, 681 
126.50, 104.34, 38.17, 10.99. IR: ν (cm–1) = 3264 (m), 2917 (w), 1055 (s), 972 (w), 828 (w). 682 
UV-Vis in DMSO: λmax nm (log ε in L mol–1 cm–1) = 282 (4.02). RP-HPLC: RT (min) = 22.3.  683 
 684 
5.3. Biological studies 685 
5.3.1. In vitro cytotoxicity testing  686 
26 
 
The cell lines used for testing included MCF-7 (human breast cancer cells possessing 687 
nuclear esstrogen receptor) and MDA-MB-231 (human breast cancer cells without nuclear 688 
estrogen receptor) were obtained from the National Cancer Institute, U.S.A. Both cell lines 689 
were cultured in RPMI-1640 / DMEM (High glucose) (Sigma) medium supplemented with 690 
10% fetal calf serum. The cells were plated into 96-well plates at cell density 6000 cells/well 691 
and incubated for 24 hours. After 24 hours, the media (5% serum) were discarded and cells 692 
rinsed with PBS solution. 200 µL of a series of concentration (50.0, 25.0, 10.0, 5.0, 1.0 and 693 
0.5 µM) for each samples prepared were added to each well. The 96-well plate was incubated 694 
for another 72 hours. After 72 hours, 96-wells plate was removed from incubator. 695 
Cytotoxicity was determined using the microtitration of 3-(4,5-dimethylthiazol-2-yl)-2,5-696 
diphenyltetrazolium bromide (MTT) assay (Sigma, USA) as reported by Mosmann [74]. 697 
20µL of MTT solution (5 mg/mL) was added to each well. The plate was wrapped with 698 
aluminium foil and incubated for 4 hours. After 4 hours, 200 µL of sample containing MTT 699 
solution was discarded from the well. 200 µL of DMSO was added to each well to dissolve 700 
the formazan crystals formed. The effect of the compound on cell lines viability was 701 
measured on an automated spectrophotometric plate reader (model MRX II microplate Elisa 702 
reader) at a test wavelength of 570 nm. Cytotoxicity was expressed as IC50, i.e. the 703 
concentration that reduced the absorbance of treated cells by 50% with reference to the 704 
control (untreated cells). The IC50 were determined from the plotted absorbance data for the 705 
dose-response curves. Controls that contained only cells were included for each sample. 706 
Tamoxifen was used as the cytotoxic standard.  707 
 708 
5.3.2. Antimicrobial testing 709 
5.3.2.1. Bacterial strains, culture media and chemicals 710 
The bacteria used in this study are listed in Table 7. The microorganisms studied 711 
included reference (from the American Type Culture Collection) and clinical (Laboratory 712 
collection) strains of Gram-negative bacteria  Escherichia coli, Enterobacter aerogenes, 713 
Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa and Salmonella 714 
enterica serotype Typhimurium as well as Gram-positive strain Staphylococcus aureus. 715 
EA289 is an Enterobacter aerogenes KANS (susceptible to kanamycin, MDR isolate that 716 
exhibits active efflux of norfloxacin and AcrAB-TolC pump overproduction), EA298 717 
constructed from EA289 is deleted of TolC [76]. AG100 is an E. coli Wild Type (WT) and 718 
AG100A is its KANR (resistant to kanamycin) derivative, deleted of AcrAB and 719 
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hypersensitive to chloramphenicol, tetracycline, ampicillin and nalidixic acid [77]. Strains 720 
were grown at 37°C on Mueller-Hinton medium 24 h prior to any assay. Mueller-Hinton 721 
broth (MHB) was used for the susceptibility test. Chemicals polymyxin B nonapeptide 722 
(PMBN) was obtained from Sigma-Aldrich and the culture medium was purchased from 723 
Becton Dickinson. 724 
Table 7: Bacteria strains. 725 
 726 
 727 
 728 
 729 
 730 
 731 
 732 
 733 
 734 
 735 
 736 
 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
 745 
 746 
 747 
 748 
 749 
 750 
 751 
 752 
 753 
 754 
 755 
KANR, resistance to kanamycin 756 
 757 
 758 
Bacteria 
strains Features References 
Escherichia coli 
AG100 Wild-type E. coli K-12 [77] 
AG100A AG100 ΔAcrAB::KANR [77] 
Enterobacter aerogenes 
EA289 
KAN sensitive 
derivative of EA27 [76] 
EA294 EA289 AcrA::KANR [76] 
EA298 EA 289 TolC::KANR [76] 
Acinetobacter baumannii 
ATCC19606 Reference strain - 
Klebsiella pneumoniae 
ATCC12296 Reference strain - 
Pseudomonas aeruginosa 
PA 01 Reference strain - 
Salmonella enterica serotype Typhimurium 
SL696 Wild-type, metA22, 
trpB2, strAi20 [78] 
Staphylococcus aureus 
SA1199 Wild-type clinical, 
methicillin-susceptible 
[79] 
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5.3.2.2. Determination of bacterial susceptibility 759 
The respective minimum inhibitory concentrations (MIC) of the samples against 760 
targeted bacteria were determined using the microdilution method (CLSI) [80]. 761 
Susceptibilities were determined in 96-well microplates with an inoculum of 2 × 105 cfu in 762 
200 µL of MHB containing two-fold serial dilutions of samples. MICs were determined in 763 
the presence of 5% or 0.5% of DMSO. In the first case, a 20× concentration range of each 764 
compound was prepared in DMSO 100%. In the second case, a 200× concentration range of 765 
each compound was prepared in DMSO 100% and then diluted with H2O to obtain a 20× 766 
concentration range in DMSO 10%. Then 10 µl of these ranges were added to 190 µl of 767 
inoculum reducing the DMSO concentration to 0.5%. The MICs of samples were determined 768 
after 18 h incubation at 37°C, following addition (50 μl) of 0.2 mg/mL iodonitrotetrazolium 769 
(INT) and incubation at 37°C for 30 minutes. MIC is defined as the lowest sample 770 
concentration that prevented the color change of the medium and exhibited complete 771 
inhibition of microbial growth. The sample dilution range was from 0-128 µM. Samples were 772 
tested alone or in the presence of PMBN at 51.2 mg/L final concentration (1/5 of its direct 773 
MIC). All assays were performed in duplicate or triplicate.  774 
 775 
5.4. X-ray crystallography  776 
X-ray diffraction measurements for SBPY were performed at 100 K on a Bruker 777 
Kappa X8 APEXII CD diffractometer with graphite monochromatised MoKα radiation (λ = 778 
0.71073 Å).  Correction for absorption was based on multi-scans [81].  Intensity data for 779 
SMHDH2, CuSMHD and CuSBHD were measured at 150 K on an Oxford Diffraction 780 
Gemini CCD diffractometer employing either CuKα (SMHDH2), λ = 1.54184 Å, or MoKα 781 
radiation (CuSMHD and CuSBHD).  Again, the corrections for absorption were based on 782 
multi-scans [82].  The structures were solved by direct methods and refined (anisotropic 783 
displacement parameters, H atoms in the riding model approximation and a weighting 784 
scheme of the form w = 1/[σ2(Fo2) + aP2 + bP] where P = (Fo2 + 2Fc2)/3) F2 using SHELX 785 
programs [83] through the WinGX interface [84].  Crystal data and refinement details are 786 
collated in Table 2.  The molecular structures shown in Figs 1-4 were drawn with 70% 787 
displacement ellipsoids using ORTEP-3 for Windows [84].  The overlay diagram, Fig. 4b, 788 
was drawn with QMol [85] and the crystal packing diagrams with DIAMOND [86]. 789 
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List of abbreviations 798 
 799 
A. baumannii Acinetobacter baumannii 
CV Cyclic voltammetry 
DMEM   Dulbecco's modified Eagle's medium  
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DMSO-d6 Deuterated dimethyl sulfoxide 
E. aerogenes Enterobacter aerogenes 
E. coli Escherichia coli 
EPR  Electron paramagnetic resonance 
ESI-MS Electrospray ionization-mass spectra  
FT-IR Fourier transform-infrared spectroscopy  
INT Iodonitrotetrazolium  
KANR  Resistance to kanamycin 
KANS Sensitive to kanamycin 
K. pneumonia Klebsiella pneumonia 
LMCT Ligand-to-metal charge-transfer 
MCF-7 Human breast carcinoma cells expressing 
nuclear estrogen receptors 
MDA-MB-231 Human breast carcinoma cells not expressing 
nuclear estrogen receptors 
MDR Multidrug resistance 
MHB Mueller-Hinton broth 
MIC Minimum inhibitory concentration 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide   
NMR Nuclear magnetic resonance 
ORTEP Oak Ridge thermal ellipsoid plot 
PBS   Phosphate buffered saline 
PMBN Polymyxin B nonapeptide 
P. aeruginosa Pseudomonas aeruginosa 
ROS Reactive oxygen species 
RP-HPLC  Reversed phase-high performance liquid 
chromatography  
r. t. Room temperature 
S. enterica Salmonella enterica 
SBDTC S-benzyldithiocarbazate 
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SMDTC S-methyldithiocarbazate 
SOD Superoxide dismutase 
S. aureus Staphylococcus aureus 
UV-Vis Ultraviolet-visible 
WT Wild type 
 800 
Appendix A. Supplementary data 801 
Supplementary data related to this article can be found at X. 802 
The crystallographic data for the structural analysis of the compounds have been deposited 803 
with the Cambridge Crystallographic Data Centre, CCDC No. for SBPY is 1057065, 804 
SMHDH2 is 1057066, CuSMHD is 1057067 and for CuSBHD is 1057068.  A copy of this 805 
information may be obtained free of charge from the Director, CCDC, 12 Union Road, 806 
Cambridge CB2 1EZ, UK (Tel.: +44 (0) 1223 762911; E-mail: deposit@ccdc.cam.ac.uk). 807 
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